Cargando…

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

INTRODUCTION: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazil...

Descripción completa

Detalles Bibliográficos
Autores principales: Domingues, Gerson, Chinzon, Decio, Moraes-Filho, Joaquim Prado P., Senra, Juliana Tosta, Perrotti, Marcos, Zaterka, Schlioma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050988/
https://www.ncbi.nlm.nih.gov/pubmed/37007753
http://dx.doi.org/10.5114/pg.2022.116673
Descripción
Sumario:INTRODUCTION: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency – ANVISA. AIM: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate. MATERIAL AND METHODS: A literature search was conducted through April–May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate. RESULTS: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control – particularly at night – using currently available PPIs, this new drug class is promising. CONCLUSIONS: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.